Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features

Angelo M Taveira-DaSilva,1 Thomas C Markello,2 David E Kleiner,3 Amanda M Jones,1 Catherine Groden,2 Ellen Macnamara,2 Tadafumi Yokoyama,9 William A Gahl,2,4 Bernadette R Gochuico,4 Joel Moss1

ABSTRACT
Background Copa syndrome is a rare autosomal dominant disorder with abnormal intracellular vesicle trafficking. The objective of this work is to expand the knowledge about this disorder by delineating phenotypic features of an unreported COPA family.

Methods and results A heterozygous missense variant (c.698 G>A, p.Arg233His) in COPA was identified in four members of a three-generation kindred with lung, autoimmune and malignant disease of unknown aetiology. Ages of onset were 56, 26, 16 and 1 year, with earlier age of onset in successive generations. Presenting symptoms were cough and dyspnoea. Findings included small lung cysts, follicular bronchiolitis, interstitial lung disease, neuroendocrine cell hyperplasia, rheumatoid arthritis, avascular necrosis and select abnormal autoimmune serologies. Neither alveolar haemorrhage nor glomerular disease were present. Features not previously associated with Copa syndrome included neuromyelitis optica, pulmonary carcinoid tumour, clear cell renal carcinoma, renal cysts, hepatic cysts, nephrolithiasis, pyelonephritis and meningitis. Longitudinal evaluations demonstrated slow progression of lung disease and extrapulmonary cysts.

Conclusions Worsening severity with successive generations may be observed in Copa syndrome. Extrapulmonary cysts, malignancies, autoimmune neurological disorders and infections are clinical features that may be associated with Copa syndrome. Further studies are indicated to fully define the phenotypic spectrum of this disorder.

INTRODUCTION
Copa syndrome (MIM: 616414) is a multisystemic autosomal dominant disorder with incomplete penetrance characterised by dysfunctional cellular trafficking; it primarily involves the lungs, kidneys and joints.1 Alveolar haemorrhage, a major pulmonary feature of Copa syndrome, is associated with interstitial lung disease, follicular bronchiolitis and lung cysts.2 Renal involvement includes glomerular disease with or without immune complex deposition. Proteinuria and reduced renal function have been observed.3 Humoral autoimmunity and inflammatory polyarticular arthritis involving the knees and small joint of the hands are other manifestations.1,3 Most previously described patients presented before the sixth year of life. Patients are generally treated with immunosuppressants; some with severe pulmonary disease underwent lung transplantation.3,4 COPA encodes the alpha subunit of coatamer complex-I (COPI), which functions in the retrograde trafficking of proteins from the Golgi to the endoplasmic reticulum (ER).3,6 Nine previous kindreds have been reported with missense variants mapping to the WD40 domain of the COPA protein, along with two other reports.1,7,8 Four COPA variants in this highly conserved region are predicted to be deleterious.3 Investigations into pathogenesis of disease showed cellular dysfunction with normal levels of COPA transcript and COPA protein in cells from patients with Copa syndrome.3

We report two male and two female patients in a new kindred with Copa syndrome and show earlier age of onset of symptomatic lung disease in three successive generations. Exome analysis identified a missense variant in the COPA WD40 domain. In addition, there are atypical manifestations in these four affected patients. The clinical presentation and natural history for this kindred expand the phenotype of Copa syndrome.

MATERIALS AND METHODS
Patient consent and ethics approval
Written informed consent was obtained. Patients were enrolled in clinical protocols 95H-0186 (Clinical Trials NCT00001465), 96H-0100 (Clinical Trials NCT00011532) and/or 76-HG-0238 (Clinical Trials NCT00369421). The patients were enrolled in the National Institute of Health (NIH) Undiagnosed Diseases Programme.9-11 Clinical evaluations were performed at the NIH Clinical Centre in Bethesda, Maryland, USA.

Pulmonary function testing
Forced vital capacity, forced expiratory volume in 1 s, total lung capacity and diffusion capacity were measured (Vmax Encore, Vyair Medical, Yorba Linda, California, USA).12

Clinical imaging
Conventional and high-resolution chest CT scans, abdominal CT scans and abdominal and brain MRI were performed.13–15

Histopathology
Tissue specimens from the proband and her father were obtained by clinically indicated open lung biopsies. Kidney tissue from the proband’s father was procured from his clinically indicated renal
mass resection. Sections were stained with H&E; immunohistochemistry for synaptophysin was performed on lung tissue from the proband’s father.

Genetic analysis
Genomic DNA was isolated from peripheral blood of family members evaluated at the initial NIH admission. Three affected adult patients and the unaffected proband’s mother were analysed by whole exome sequencing.16 A heterozygous variant (c.698 G>A, p.Arg233His) in COPA segregated with affected status. Sanger sequencing confirmed this variant in these patients and the proband’s son (GeneDx, Gaithersburg, Maryland, USA).

RESULTS
Clinical manifestations of disease
Four affected patients in three successive generations were studied (figure 1A). The proband presented at 16 years of age with cough, wheezing and chest pain. She was diagnosed with hypersensitivity pneumonitis, unresponsive to corticosteroid therapy. Dyspnoea on exertion developed at 18 years of age. At 20 years of age, nephrolithiasis was detected, and a CT scan revealed cystic lung lesions. She was referred to the NIH Clinical Center with a presumptive diagnosis of lymphangioleiomyomatosis (LAM) at 21 years of age; lung function testing revealed restriction and impaired diffusion capacity. Rheumatoid factor, antinuclear factor, anticyclopentapeptide antibody, antinuclear antibody, sedimentation rate and C-reactive protein were normal. Serum cystatin-C and beta-2 microglobulin were mildly elevated. Blood urea nitrogen, serum creatinine, urinalysis and 24 hours creatinine clearance were normal.

The sister had hearing loss due to bacterial meningitis at 2 years of age and bilateral recurrent neurourymatitis optica starting at age 6. She was evaluated at the NIH Clinical Center at 26 years of age with dyspnoea on exertion and a presumptive diagnosis of LAM. Chest CT scan showed lung cysts. Her baseline evaluation showed restriction and severely reduced diffusion capacity. Elevated serum anticyclopentapeptide antibody, cystatin-C and beta-2 microglobulin levels were measured. Urine sediment showed 26 red blood cells/μL (normal <15) without casts. Rheumatoid factor, antinuclear antibody, sedimentation rate, C-reactive protein, blood urea nitrogen, serum creatinine, urine protein and 24 hours creatinine clearance were normal.

The proband’s 56-year-old father was asymptomatic. Given his daughters’ lung disease, an inherited disorder was considered, and he was carefully phenotyped to assign affected/unaffected status. His evaluation revealed normal lung volumes, but mildly reduced diffusion capacity. Anticyclopentapeptide antibody, antinuclear antigen, sedimentation rate, C-reactive protein, urinalysis and creatinine clearance were within normal limits. Rheumatoid factor, serum cystatin C and serum beta-2 microglobulin were mildly increased.

The proband’s son was not part of the original NIH evaluation. He presented with intermittent severe coughing paroxysms throughout childhood following respiratory syncytial virus infection at 1 year of age. At 7 years of age, chest CT revealed diffuse tiny lung nodules with a ‘tree-in-bud’ appearance and a small lung cyst. He was confirmed to have the familial COPA gene variant and was subsequently evaluated at the NIH Clinical Center. Lung function testing revealed mildly reduced diffusion capacity. Serologies were normal. Serum cystatin C and beta-2 microglobulin were slightly elevated. Urine was negative for protein, red blood cells and casts.

Imaging findings
Chest CT scans were performed during the NIH Clinical Center evaluations. The proband and sister showed a diffuse interstitial infiltrative process and scattered cystic lesions not characteristic of LAM (figure 1B). Other imaging studies failed to demonstrate any of the extrapulmonary manifestations of LAM. The proband’s renal ultrasound revealed a right renal cyst. Chest CT scans of the asymptomatic father demonstrated discrete cystic lung lesions and several lung nodules suspicious for malignancy (figure 1C and D). The proband’s son’s CT scan at 7 years of age showed a diffuse interstitial pattern and a lung cyst. A necrotic right kidney lesion was interpreted as an incidental finding in the proband’s father (figure 1E).

Histopathology of lung and kidney tissue
The proband’s lung biopsy showed findings consistent with follicular bronchiolitis. Numerous reactive lymphoid follicles were localised within peribronchovascular and subpleural regions (figure 1F). Emphysema and collections of foamy histiocytes were present. Alveolar haemorrhage was not found in the histological sections.

The father underwent lung biopsy and lung nodule resection. Pathology showed respiratory bronchiolitis, diffuse lymphoid aggregates, emphysema, neuroendocrine hyperplasia and a carcinoid tumour (figure 1G and H). He also underwent a partial nephrectomy. Histopathology revealed clear cell renal carcinoma (figure 1I). Examination of surrounding non-malignant renal tissue did not demonstrate glomerular disease.

Genetic testing
Agnostic exome sequencing of the proband, sister and both parents identified a heterozygous variant (c.698 G>A, p.Arg233His) in COPA in the father and two offspring; this was Clinical Laboratory Improvement Amendments confirmed by Sanger sequencing. Targeted analysis of DNA from the son revealed the same heterozygous variant in COPA. Sanger sequencing for this variant was negative in three unaffected relatives (an aunt and two first cousins).

Longitudinal clinical evaluations
The adult patients underwent serial evaluations over 11 years at the NIH Clinical Center. The proband’s dyspnoea slowly progressed and hypoxaemia developed at 23 years of age. Longitudinal data showed gradual decline of lung function. Chest CT scans showed progression in the appearance of innumerable small lung cysts, onset of fibrosis, lung nodule development and progressive multiple mediastinal lymph node enlargement. Abdominal imaging revealed increased size and number of renal cysts. Avascular necrosis of her femur and tibia were diagnosed at 28 years of age. Rheumatoid arthritis manifested at 29 years of age. C-reactive protein and rheumatoid factor increased to 5 mg/mL (normal 0–4.99 mg/L) and 98 IU/mL (normal <20 IU/mL), respectively; antinuclear antibody remained negative. Acute pylonephritis occurred at 32 years of age.

The older sister has remained clinically stable, but lung function tests have demonstrated onset of airflow obstruction, and chest imaging revealed diffuse bronchial wall thickening and a new small lung nodule. Neuroumyelitis optica with severe visual deficit was unchanged in the sister.

The father, who was initially asymptomatic, developed intermittent cough. Serial pulmonary function testing demonstrated gradual development of lung restriction with stable diffusion capacity. Chest CT scans showed innumerable punctate lung

Phenotypes

Taveira-DaSilva AM, et al. J Med Genet 2018;0:1–5. doi:10.1136/jmedgenet-2018-105560
cysts, multiple pulmonary nodules and diffuse bronchial wall thickening. Abdominal MRI detected hepatic cysts.

**DISCUSSION**

Previous cases affected by Copa syndrome provided the initial insights into the phenotypic pleiotropy of this rare autosomal dominant disorder (table 1). The current kindred contains individuals with some typical features of the disease, including lung cysts, follicular bronchiolitis, interstitial lung disease, neuroendocrine cell hyperplasia, positive autoimmune serologies and arthritides (table 1). Avascular necrosis, which was reported in another patient with Copa syndrome, also developed in the
Table 1  Clinical manifestations in patients with COPA variants

| COPA variant | Affected kindreds (patients) | Ethnicity/ nationality | Lung | Kidney | Rheumatology/ autoimmune | Other | References |
|--------------|-----------------------------|------------------------|------|--------|---------------------------|-------|------------|
| p.Arg233His  | 1 (4) White, African American | FB, ILD, cysts, carcinoid tumour | Clear cell carcinoma | Arthritis, AVN, neuromyelitis optica | Liver/renal cysts, nephrolithiasis, nephritis, meningitis, RSV infection | This report |
| p.Arg233His  | 3 (9) White, Asian | FB, ILD, AH, cysts | Glomerulonephritis | Arthritis, AVN, thyroid disease | | Watkin et al, Volpi et al |
| p.Asp243Gly  | 1 (3) White | ILD, AH | Glomerulonephritis, tubular disease | Arthritis | | Watkin et al |
| p.Glu241Lys  | 2 (8) White, Icelandic | FB, ILD, AH, cysts, neuroendocrine cell hyperplasia | Glomerulonephritis | Arthritis | Recurrent respiratory infections | Watkin et al, Jenson et al |
| p.Lys230Asn  | 1 (5) White | ILD, AH | Glomerulonephritis | | Dyskinesia | Watkin et al |
| p.Trp240Arg  | 1 (1) African American | ILD, AH?, cysts | | Arthritis | Failure to thrive | Noorelahi et al |
| p.Asp243Asn  | 1 (1) NR | ILD, inflammation, aspiration | | Arthritis, MAS | GORD | Brennan et al |

AH, alveolar haemorrhage; AVN, avascular necrosis; FB, follicular bronchitis; GORD, gastro-oesophageal reflux disease; ILD, interstitial lung disease; MAS, macrophage activation syndrome; NR, not reported; RSV, respiratory syncytial virus.

The presented kindred exhibited some new/atypical manifestations (table 1). One affected patient had severe vision loss due to neuromyelitis optica, an autoimmune disorder associated with autoantibodies against aquaporin-4. Extrapulmonary cysts in the liver and kidney, nephrolithiasis, infection (ie, acute pyelonephritis, meningitis, respiratory syncytial virus) and malignancies (ie, carcinoid tumour, renal cell carcinoma) were diagnosed in at least one affected patient; these have not been reported in patients with Copa syndrome. Cancers are known to occur in at least one affected patient; these have not been reported in patients with Copa syndrome. Notably, these three patients have different COPA variants and are responsible for the overall content as guarantor(s).

Acknowledgements The authors thank our patients for their participation in our studies. Contributors All authors contributed to the acquisition, analysis or interpretation of data, revised the manuscript critically for important intellectual content and approved the version to be published. A.M.T.-D., T.C.M., W.A.G., B.R.G. and J.M. contributed to the conception of this work. A.M.T.-D., T.C.M., B.R.G. and J.M. drafted the manuscript and are responsible for the overall content as guarantor(s).

Funding This research was supported by the Intramural Research Programs of the National Heart, Lung and Blood Institute, the Office of the Director, the National Cancer Institute and the National Human Genome Research Institute, National Institutes of Health.

Competing interests None declared.

Patient consent Obtained.

Ethics approval National Heart, Lung and Blood Institute or National Human Genome Research Institute.

Provenance and peer review Not commissioned; externally peer reviewed.

Thirty-two individuals with Copa syndrome, including four patients in this family, are reported, and it is unclear whether there is a genotype–phenotype association. An Arg233His variant was found in four kindreds with 13 affected patients. Longitudinal analysis for our patients demonstrated slowly progressive cystic lung disease and follicular bronchiolitis. In contrast, follicular bronchiolitis in a 32-year-old woman and her 11-year-old son with a Glu241Lys variant progressed, and they received lung transplants. Although the Glu241Lys variant is associated with severe lung disease, it has not been reported in patients with Copa syndrome and kidney disease.

In conclusion, this family with Copa syndrome includes four affected individuals who are heterozygous for a missense COPA variant. This family has manifestations not reported in other patients with Copa syndrome, including neuromyelitis optica, extrapulmonary cysts and renal and neuroendocrine malignancies. Furthermore, the slow progression of follicular bronchiolitis differs from the more rapidly progressive disease observed in another kindred with a different COPA variant, which suggests that there may be variable expression associated with Copa syndrome. Overall, the identification of unreported clinical features in this family with Copa syndrome provides new insights into pathogenic mechanisms and hints that the phenotypic spectrum of this disorder is not yet fully defined.
Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1 Watkin LB, Jessen B, Wiszniewski V, Vece TJ, Jan M, Sha’Y, Thamsen M, Santos-Cortez RL, Lee K, Gambin T, Forbes LR, Law CS, Stray-Pedersen A, Cheng MH, Mace EM, Anderson MS, Liu D, Tang LF, Nicholas SK, Nahmod K, Malekodinas G, Canter DL, Kwock PY, Hicks J, Jones KD, Penney S, Jiangiani SN, Rosenblum MD, Dell SD, Waterfield MR, Papa FR, Muzny DM, Zaitlen N, Leal SM, Gonzaga-Jauregui C, Boerwinkle E, Eissa NT, Gibbs RA, Lupski JR, Orange JS, Shum AK. Baylor-Hopkins Center for Mendelian Genomics. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. *Nar Genet* 2015;47:654–60.

2 Tsui JL, Estrada OA, Deng Z, Wang KM, Law CS, Eicker BM, Jones KD, Dell SD, Gudmundsson G, Hansdottir S, Heltgot SM, Volpi S, Gattorno M, Waterfield M, Chan AV, Chung SA, Ley B, Shum AK. Analysis of pulmonary features and treatment approaches in the COPA syndrome. *ERJ Open Res* 2018;4:2018.

3 Vece TJ, Watkin LB, Nicholas S, Canter D, Braun MC, Guillerman RP, Eldin KW, Bertoelet G, McKinley S, de Guzman M, Forbes LR, Chinn I, Orange JS. COPA syndrome: a novel autosomal dominant immune dysregulatory disease. *J Clin Immunol* 2016;36:377–87.

4 Jensson BO, Hansdottir S, Arnadottir GA, Sulem P, Kristjansson JH, Bjornsson J, Magnusson OT, Masson G, Thorisson GA, Jonassdotir A, Jonasdottir A, Sigurdsson A, Ionsdottir I, Petursdottir V, Kristinsson JR, Gudjardottir DF, Thorsteinsdottir U, Arngrimsson R, Sulem P, Gudmundsson G, Stefansson K. COPA syndrome in an Icelandic family caused by a recurrent missense mutation in COPA. *BMCMedGenet* 2017;18:129.

5 Quik HH, Chow VT. Molecular and cellular studies of the human homolog of the 160-kD alpha-subunit of the coatamer protein complex. *DNA Cell Biol* 1997;16:275–80.

6 Shima DT, Scales SJ, Kreis TE, Peperkok R. Segregation of COP1-rich and anterograde-cargo-rich domains in endoplasmic-reticulum-to-Golgi transport complexes. *Curr Biol* 1999;9:821–4.

7 Nooren A, Perez G, Otero HI. Imaging findings of COPA syndrome in a 12-year-old boy. *Pediatr Radial* 2018;48:279–82.

8 Brennan MD, McDougall C, Walsh J, Crow YJ, Davidson J. 013. COPA syndrome - a new condition to consider when features of polyarthritis and interstitial lung disease are present. *Rheumatol J* 2017;56.

9 Gahl WA, Tifft CI. The NIH Undiagnosed Diseases Program: lessons learned. *JAMA* 2011;305:1904–5.

10 Gahl WA, Markello TC, Toro C, Fajardo KE, Sincan M, Gill F, Carlson-Donohoe H, Gropman A, Persson TM, Golas G, Wolfe L, Groden C, Godfrey R, Nehrebecky M, Wahl C, Landis DM, Yang S, Madoe A, Mullikin JC, Boerkoel CF, Tifft CI, Adams D. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. *Genet Med* 2012;14:51–9.

11 Gahl WA, Mulvihill JJ, Toro C, Markello TC, Wise AL, Ramoni RB, Adams DR, Tifft CI; UDNI. The NIH Undiagnosed Diseases Program and Network: applications to modern medicine. *Mol Genet Metab* 2016;117:393–400.

12 Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, Travis WD, McCoy JP, May RM, Wu HP, Nguyen DM, Arocs-Burgos M, MacDonald SD, Gochucho BR. Early interstitial lung disease in familial pulmonary fibrosis. *Am J Respir Crit Care Med* 2007;176:698–705.

13 Gochucho BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med* 2008;168:159–66.

14 Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangiolyiomatosis: abdominopelvic CT and US findings. *Radiology* 2000;216:147–53.

15 Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A. Meningiomas in lymphangiolyiomatosis. *JAMA* 2001;286:1879–81.

16 Gall T, Valkenars E, Bello C, Markello T, Adams C, Bone WP, Brandt AJ, Buzil JM, Carmichael L, Davids M, Davis J, Diaz-Perez Z, Draper D, Elson J, Flynn ED, Godfrey R, Groden C, Hsieh CK, Fischer R, Golas GA, Guzman J, Huang Y, Kane MS, Lee E, Li C, Links AE, Maduro V, Malicdan MC, Mall F, Nehrebecky M, Park J, Piermont P, Schaffer K, Simeonov D, Sincan M, Smedley D, Valivullah Z, Wahl C, Washington N, Wolfe LA, Xu K, Zhu Y, Gahl WA, Tifft CI, Toro C, Adams DR, He M, Robinson PN, Haendel MA, Zhai RQ, Boerkoel CF, disease D. Defining disease, diagnosis, and translational medicine within a homeostatic perturbation paradigm: the National Institutes of Health Undiagnosed Diseases Program experience. *Front Med* 2017;4:62.

17 Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, Ravelli A, Shum AK, Gattorno M, Picco P. Type I interferon pathway activation in COPA syndrome. *Clin Immunol* 2018;187:33–6.

18 Lennon VA, Kryzer TJ, Pittcock SJ, Verkman AS, Hinson SR. IgG marker of optic-spiral multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med* 2005;202:473–7.

19 Hill CL, Zhang Y, Sigurgeirsson B, Pukkela E, Mellemkjaer L, Aino V, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. *Cancer* 2001;95:96–100.

20 Bernatsky S, Boivin JF, Joseph L, Raja R, Zoma A, Manzi S, Ginzier E, Uhrmick M, Gladman D, Fortin PR, Petri M, Edworthy S, Bar S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ewosworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. *Arthritis Rheumat* 2005;52:1481–90.